RxDoctor Payments Data

Gregory Sanders, MD

Cardiovascular Disease · Phoenix, AZNPI 1811989528

Payments from drug & device makers

$9,150in general payments, 2019–2025

Across 479 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Amgen$1K
  • Merck$787
  • Johnson & Johnson$771
  • AstraZeneca$472
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$440
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,117100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,150 in reported general payments places this provider in the 70th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$488,518
Medicare patients
1,203
Services billed
5,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban693$784,367
EntrestoSacubitril/Valsartan215$252,738
JardianceEmpagliflozin219$232,896
XareltoRivaroxaban144$174,247
Repatha SureclickEvolocumab115$103,776
FarxigaDapagliflozin Propanediol69$56,561
Praluent PenAlirocumab46$30,306
MultaqDronedarone Hcl12$18,306
NexletolBempedoic Acid12$7,952
Metoprolol Succinate512$7,268
Rosuvastatin Calcium515$6,228
Midodrine Hcl56$5,916
Nebivolol Hcl83$5,743
Ranolazine ErRanolazine35$4,870
Atorvastatin Calcium515$4,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$382$784,367693 claims
NovartisEntresto$1,296$252,738215 claims
Boehringer IngelheimJardiance$428$232,896219 claims
Johnson & JohnsonXarelto$771$174,247144 claims
AstraZenecaFarxiga$472$56,56169 claims
Sanofi-aventis U.S. LLCMultaq$42$18,30612 claims
Esperion Therapeutics, Inc.Nexletol$186$7,95212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →